Reprogramming the Immune System to Halt MG | Webinar with COUR

COUR Pharmaceuticals presents: "Reprogramming The Immune System To Halt Myasthenia Gravis: Introduction To The COUR Nanoparticle Technology And Trial In MG."

In this webinar, Dr. Paul M. Peloso, Chief Medical Officer at COUR Pharmaceuticals, addresses our MG community, providing an insightful update on the ongoing clinical trial of CNP-106, COUR’s promising investigational treatment for MG. He also highlights the various resources and support systems available to study participants to help them feel supported.

Learn more about COUR: courpharma.com

--------

Follow Us!

Website: www.myastheniagravis.org
Facebook: www.facebook.com/ConquerMyastheniaGravis
Instagram: www.instagram.com/ConquerMG_IL
Twitter / X: www.twitter.com/ConquerMG
YouTube:    / @myastheniagravisorgillinois  

--------

Myasthenia Gravis (MG) is an autoimmune disease, targeting the communication point between the nerve and muscle (called the “neuromuscular junction.”) In MG, antibodies block, alter, or destroy the neurotransmitter receptors on muscle tissue. Since the muscles can’t receive the signal to contract, people with myasthenia become weak. MG causes weakness in voluntary muscles that worsens with activity and improves with rest.

MG’s primary symptoms fluctuate, vary in severity and occur in many combinations. Symptoms may include droopy eyelids; double or blurred vision; weak arms, hands, neck, face or legs; and excessive fatigue. When severe, MG can result in difficulty chewing, smiling, swallowing, talking or breathing.